Pharmacokinetics and pharmacodynamics of the novel H1-receptor antagonist emedastine in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 55, Issue 11-12, 2000, Pages 837-841

  Jansen, B ^a   Graselli, U ^a   Dallinger, S ^a   Kiss, B ^a   Wacheck, V ^a   Schlagbauer Wadl, H ^a   Assandri, A ^b   Muller M ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b Cross Research SA   (Switzerland)

Author keywords

Emedastine; Flares; Histamine

Indexed keywords

CETIRIZINE; EMEDASTINE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG POTENCY; HISTAMINE RELEASE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PRICK TEST; PRIORITY JOURNAL; RECEPTOR BLOCKING; SEDATION; STEADY STATE; URTICARIA; XEROSTOMIA;

EID: 0034033620     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050705     Document Type: Article

References (13)

1. Inagaki N, Sakurai T, Abe T, Musoh K, Kawasaki H, Tsunematsu M, Nagai H (1998) Characterization of antihistamines using biphasic cutaneous reaction in BALB/c mice. Life Sci 63: 145-150
2. el-Shazly AE, Masuyama K, Samejima Y, Eura M, Ishikawa T (1996) Inhibition of human eosinophil chemotaxis in vitro by the anti-allergic agent emedastine difumarate. Immunopharmacol Immunotoxicol 18: 587-595
3. Sharif NA, Xu SX, Magnino PE, Pang ICH (1996) Human conjunctival epithelial cells express histamine-1 receptors coupled to phosphoinositide turnover and intracellular calcium mobilization: role in ocular allergic and inflammatory diseases. Exp Eye Res 63: 169-178
4. Yanni JM, Stephens DJ, Parnell DW, Spellman JM (1994) Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol 10: 665-675
5. Sharif NA, Su SX, Yanni JM (1994) Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol 10: 653-664
6. Saito T, Hagihara A, Igarashi N, Matsuda N, Yamashita A, Ito K, Mio M, Tasaka K (1993) Inhibitory effects of emedastine difumarate on histamine release. Jpn J Pharmacol 62: 137-143
7. Matsuda N (1993) Effect of emedastine difumarate on platelet activating factor-induced chemotaxis of guinea pig eosinophils. Basic Pharmacol Ther 21: 1478-1485
8. Saito T, Nishimura N, Tajima S, Fukuda T, Ito K (1987) Antiallergic effects of 1-(2-ethoxethyl)-2-(4-methyl-1-homopiperazinyl) benzimidazole difumarate (KB-2413). Nippon Yakurigaku Zassi 89: 55-62
9. Nishimura N, Ito K, Tomioka H, Yoshida S (1987) Inhibition of chemical mediator release from human leukocytes and lung in vitro by a novel antiallergic agent, KB-2413. Immunopharmacol Immunotoxicol 9: 511-521
10. Saito T, Fukuda T, Sukamoto T, Yoshidomi M, Morimoto Y, Shimohara K, Ito K (1988) General pharmacology of 1-(2- ethoxyethyl)-2-(4-methyl-1-homopiperazinyl) benzimidazole difumarate. 2nd Communication: effects on the circulation and the other systems. Arzneimittelforschung 38: 267-272
11. Saito T, Fukuda T, Sukamoto T, Yoshidomi M, Morimoto Y, Shimohara K, Ito K (1988) General pharmacology of 1-(2- ethoxyethyl)-2-(4-methyl-1-homopiperazinyl) benzimidazole difumarate. 1st Communication: effects on the central nervous system. Arzneimittelforschung 38: 66-69
12. Tasaka K, Kamei C, Katayama S, Kitazumi K, Akahori H, Hokonohara T (1986) Comparative study of various H1-blockers on neuropharmacological and behavioral effects including 1-(2-ethoxethyl)-2-(4-methyl-1-homopiperazinyl) benzimidazole difumarate (KB-2413), a new antiallergic agent. Arch Int Pharmacodyn Ther 280: 275-291
13. Taudorf E, Malling HJ, Laursen LC, Lanner A, Weeke B (1985) Reproducibility of histamine skin prick test. Allergy 40: 344-349